Position in ROIV
as of Mar 31, 2026
· filed Apr 29, 2026
Position Value
$1,393,642
+$575,856 QoQ
Shares Held
50,312
+33.5% QoQ
Ownership
0.007%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ROIV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Brooklyn Investment Group holds $23,138,608 across 42 Biotechnology names. ROIV ranks #3 (6.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
6,245 | $2,788,642 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,889 | $1,459,516 | |
| 3 | ROIV |
Roivant Sciences Ltd.
This page
|
50,312 | $1,393,642 | |
| 4 | ARGX |
Argenx SE
|
1,697 | $1,239,234 | |
| 5 | MRNA |
Moderna, Inc.
|
23,110 | $1,173,988 | |
| 6 | GMAB |
Genmab A/S
|
35,823 | $961,131 | |
| 7 | ASND |
Ascendis Pharma A/S
|
4,072 | $931,388 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
8,994 | $874,666 |
All Filings in ROIV
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,393,642 | 50,312 | Shares | Defined | 2026-04-29 | |
| 2025-12-31 | $817,786 | 37,686 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $237,056 | 15,668 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $176,815 | 15,689 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $18,595 | 1,843 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $47 | 4 | Shares | Defined | 2025-01-15 | |
| No filing history on record for this holder in this stock. | ||||||